Ms. Monaco is an accomplished C-suite professional with a successful track record as a leader in the pharmaceutical industry. She has spent the last decade in the dermatology sector with an extensive track record of building start-up operations, accelerating change, and driving process improvement. Mostly recently, Erica was the CEO of Biofrontera Inc. (NASDAQ: BFRI). In her role as the CEO of Biofrontera, where she joined as “employee #2”, Erica grew a pre-commercial organization from FDA approval through market introduction and commercial launch, posting a revenue growth at a CAGR over 80% and completing an accretive M&A transaction. Under her watch Biofrontera completed a successful Initial Public Offering (IPO) listing on NASDAQ in 2021 and follow on equity investment rounds in excess of $60M. Ms. Monaco holds a Master of Accounting degree from the Isenberg School of Management at the University of Massachusetts, Amherst and holds an active CPA license.